Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NeuClone’s Trastuzumab Trial Succeeds

Reports Successful Phase I Trial For NeuCeptin Trastuzumab Biosimilar

Executive Summary

NeuClone has reported that its NeuCeptin proposed biosimilar trastuzumab has successfully met all primary and secondary endpoints in a Phase I clinical trial.

You may also be interested in...



Meiji And Dong-A Start European Ustekinumab Trial

A Phase I study will compare the pharmacokinetics, safety and tolerability of Meiji and Dong-A’s DMB-3115 ustekinumab biosimilar candidate against Janssen’s Stelara reference psoriasis and Crohn’s disease brand.

NeuClone Starts Trial For Ustekinumab Biosimilar

After extensive pre-clinical testing, NeuClone has commenced dosing in a Phase I clinical trial for its Stelara biosimilar candidate, NeuLara.

Armas Launches Four US Injectables

Armas has kicked off 2020 with the launch of four generic injectables in the US.

Topics

UsernamePublicRestriction

Register

GB149439

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel